Niels Granholm-Leth

Research Analyst at Carnegie Mellon University

Niels Granholm-Leth is Head of Equity Research at Carnegie Investment Bank, where he specializes in coverage of Nordic healthcare and medical technology companies including Ambu, Coloplast, and Demant. Granholm-Leth is known for his detailed sector analysis and is frequently cited for his insights on company performance and market developments, though specific public metrics on his investment calls or rankings are limited. Having begun his career in finance in the early 2000s, he has held senior roles within Carnegie and also serves as Chairman of the Accounting Board of the Danish Financial Society, reflecting his focus on research quality and integrity. His professional credentials include leadership in research standards, and he is recognized for his broader influence in shaping Danish equity research.

Niels Granholm-Leth's questions to GNNDY leadership

Question · Q2 2024

Aug 22, 2024

Asked about future divestment plans, the outlook for net working capital release in H2, and specifics regarding the recent retail divestment.

Answer

The company will continue its strategy of opportunistic, non-core divestments but is not in a rush. They expect a positive net working capital impact for the full year, driven by improvements in H2, including benefits from the consumer wind-down. Details on the wholesale agreement with the divested retail business were not provided.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies

Access millions of SEC filings & transcripts

Get answers cited to the source

Try Fintool for Free

Trusted by leading investment firms and analysts